Mabwell (Shanghai) Bioscience Co., Ltd. announced that Hong Kong’s Listing Rules will not require the company to publish an independent annual report or summary financial report for the financial year ended 31 December 2025.

According to Rule 13.46(2) Note 4, the exemption was granted because: 1) Mabwell’s prospectus dated 20 April 2026 already contains all financial information mandated under Appendix D2 of the Listing Rules for FY 2025. 2) The waiver does not conflict with the company’s articles of association, PRC regulations, or other disclosure requirements. 3) Mabwell met all applicable provisions in Part 2 of the Corporate Governance Code, except code provision C.2.1, for which explanations are provided in the prospectus.

As a result, shareholders will not receive a separate FY 2025 annual report. The company will, however, publish a standalone 2025 Environmental, Social and Governance Report. Investors can access the FY 2025 financial statements in the prospectus available on both the HKEX news website and Mabwell’s corporate site.

The announcement was authorized by Chairman and Executive Director Dr. Liu Datao on 30 April 2026 in Shanghai. The board currently comprises six executive directors, one non-executive director, and four independent non-executive directors.